Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic anemia

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective and curative treatment option for patients with aplastic anemia (AA). High-dose cyclophosphamide (CY) (200 mg/kg) combined with anti-thymocyte globulin (ATG) is frequently used as a conditioning regimen, and shows excellent outcomes especially in HSCT from a human leukocyte antigen (HLA)-matched sibling [1]. However, the cardiotoxicity of high-dose CY is a major problem [2], since patients with AA often have cardiac dysfunction due to long-term anemia and iron overload associated with massive transfusion.

Source: Biology of Blood and Marrow Transplantation - October 12, 2019 Category: Hematology Authors: Shinichi Kako, Hirohito Yamazaki, Kazuteru Ohashi, Yukiyasu Ozawa, Shuichi Ota, Yoshinobu Kanda, Tetsuo Maeda, Jun Kato, Ken Ishiyama, Ken-ichi Matsuoka, Toshihiro Miyamoto, Hiroatsu Iida, Kazuhiro Ikegame, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta Source Type: research